Cinryze and Haegarda Comparison

Cinryze®(C1 esterase inhibitor (human))	Haegarda®(C1 esterase inhibitor (human))
Prescription Only Cinryze is a synthetic version of a protein found naturally in the bloodstream, which plays a vital role in regulating inflammation in the body. Individuals with a condition known...	Prescription Only Haegarda is a synthetic version of a blood protein that regulates swelling in the body. Individuals with Hereditary Angioedema (HAE) lack sufficient levels of this protein,...
Administration
Intravenous. Learn more.	Subcutaneous . Learn more.
Dosing
Adults and Children >12: 1,000 IU Intravenous every 3 or 4 days. Children 6-11: 500 IU Intravenous every 3 or 4 days.. Learn more.	Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).. Learn more.
Latin Shorthand
Adults and Children >12: 1,000 IU IV q3-4d. Children 6-11: 500 IU IV q3-4d.. Learn more.	Administer 60 IU/kg BW BID (q3-4d).. Learn more.
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	Learn more.
Annual Cap
$40,000. Learn more.	Learn more.
Assistance Expiration
Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever.. Learn more.	Adverse reactions occurring in more than 4% of subjects treated with HAEGARDA were injection site reactions, hypersensitivity, nasopharyngitis and dizziness.. Learn more.
Mechanism of Actions (MoA)
Drugs used in Hereditary Angioedema. Learn more.	Drugs used in Hereditary Angioedema. Learn more.
Special Populations
1. Is CINRYZE safe to use during pregnancy? There are no specific data available regarding the use of CINRYZE in pregnant women. Animal studies have not been conducted to assess its effects on pregnancy. Whether CINRYZE can cause harm to a developing fetus or affect reproductive capacity in pregnant women is unknown. It should only be administered to a pregnant woman if it is clearly needed. 2. What is the background risk of birth defects and miscarriage in the general U.S. population? In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4%, and the risk of miscarriage is estimated to be 15 to 20%. 3. Is there any information on the use of CINRYZE during lactation? There is no available data regarding the presence of CINRYZE in human milk, its effects on breastfed infants, or its impact on milk production. When considering the use of CINRYZE, the benefits of breastfeeding, both for the infant's development and the mother's clinical need, should be weighed against any potential adverse effects on the breastfed child. 4. Has CINRYZE been tested in pediatric patients? Yes, the safety and effectiveness of CINRYZE have been evaluated in pediatric subjects with hereditary angioedema (HAE) aged 7 to 11 years old. Additionally, some subjects under the age of 18 were included in trials, and overall, the safety and tolerability of CINRYZE were found to be similar in pediatric, adolescent, and adult subjects. The pharmacokinetics of CINRYZE were also assessed in pediatric subjects aged 7 to 11 years old. 5. Is CINRYZE suitable for use in geriatric patients? Clinical studies of CINRYZE did not include a sufficient number of subjects aged 65 and over to determine if they respond differently from younger subjects. Reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for an elderly patient should be cautious, typically starting at the lower end of the dosing range, considering the higher likelihood of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.	1. Is it safe to use HAEGARDA during pregnancy? There are no prospective clinical data from HAEGARDA use in pregnant women. However, limited retrospective data suggest that C1-INH treatment during pregnancy did not lead to adverse events. The estimated background risk of birth defects and miscarriage in the general U.S. population is 2-4% and 15-20%, respectively. 2. What is known about HAEGARDA use during lactation? There is no information available about the presence of HAEGARDA in human milk, its impact on breastfed infants, or its effects on milk production. The decision to breastfeed should consider the benefits of breastfeeding and the mother's clinical need for HAEGARDA, while also evaluating potential adverse effects on the breastfed infant. 3. Has HAEGARDA been tested in pediatric patients? Yes, the safety and effectiveness of HAEGARDA were evaluated in a subgroup of patients aged 8 to <17 years in clinical trials, and the results were consistent with overall study results. 4. Is HAEGARDA suitable for use in geriatric patients? Clinical studies of HAEGARDA did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects. However, reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for elderly patients should be cautious and typically start at the lower end of the dosing range, considering factors like decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.

Cinryze®(C1 esterase inhibitor (human))

Haegarda®(C1 esterase inhibitor (human))

Prescription Only

Cinryze is a synthetic version of a protein found naturally in the bloodstream, which plays a vital role in regulating inflammation in the body. Individuals with a condition known...

Prescription Only

Haegarda is a synthetic version of a blood protein that regulates swelling in the body. Individuals with Hereditary Angioedema (HAE) lack sufficient levels of this protein,...

Dosage & Administration

Administration

Intravenous. Learn more.

Subcutaneous . Learn more.

Dosing

Adults and Children >12: 1,000 IU Intravenous every 3 or 4 days. Children 6-11: 500 IU Intravenous every 3 or 4 days.. Learn more.

Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).. Learn more.

Latin Shorthand

Adults and Children >12: 1,000 IU IV q3-4d. Children 6-11: 500 IU IV q3-4d.. Learn more.

Administer 60 IU/kg BW BID (q3-4d).. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$0. Learn more.

Learn more.

Annual Cap

$40,000. Learn more.

Learn more.

Assistance Expiration

Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever.. Learn more.

Adverse reactions occurring in more than 4% of subjects treated with HAEGARDA were injection site reactions, hypersensitivity, nasopharyngitis and dizziness.. Learn more.

Mechanism of Actions (MoA)

Drugs used in Hereditary Angioedema. Learn more.

Special Populations

1. Is CINRYZE safe to use during pregnancy?

There are no specific data available regarding the use of CINRYZE in pregnant women. Animal studies have not been conducted to assess its effects on pregnancy. Whether CINRYZE can cause harm to a developing fetus or affect reproductive capacity in pregnant women is unknown. It should only be administered to a pregnant woman if it is clearly needed.

2. What is the background risk of birth defects and miscarriage in the general U.S. population?

In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4%, and the risk of miscarriage is estimated to be 15 to 20%.

3. Is there any information on the use of CINRYZE during lactation?

There is no available data regarding the presence of CINRYZE in human milk, its effects on breastfed infants, or its impact on milk production. When considering the use of CINRYZE, the benefits of breastfeeding, both for the infant's development and the mother's clinical need, should be weighed against any potential adverse effects on the breastfed child.

4. Has CINRYZE been tested in pediatric patients?

Yes, the safety and effectiveness of CINRYZE have been evaluated in pediatric subjects with hereditary angioedema (HAE) aged 7 to 11 years old. Additionally, some subjects under the age of 18 were included in trials, and overall, the safety and tolerability of CINRYZE were found to be similar in pediatric, adolescent, and adult subjects. The pharmacokinetics of CINRYZE were also assessed in pediatric subjects aged 7 to 11 years old.

5. Is CINRYZE suitable for use in geriatric patients?

Clinical studies of CINRYZE did not include a sufficient number of subjects aged 65 and over to determine if they respond differently from younger subjects. Reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for an elderly patient should be cautious, typically starting at the lower end of the dosing range, considering the higher likelihood of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.

1. Is it safe to use HAEGARDA during pregnancy?

There are no prospective clinical data from HAEGARDA use in pregnant women. However, limited retrospective data suggest that C1-INH treatment during pregnancy did not lead to adverse events. The estimated background risk of birth defects and miscarriage in the general U.S. population is 2-4% and 15-20%, respectively.

2. What is known about HAEGARDA use during lactation?

There is no information available about the presence of HAEGARDA in human milk, its impact on breastfed infants, or its effects on milk production. The decision to breastfeed should consider the benefits of breastfeeding and the mother's clinical need for HAEGARDA, while also evaluating potential adverse effects on the breastfed infant.

3. Has HAEGARDA been tested in pediatric patients?

Yes, the safety and effectiveness of HAEGARDA were evaluated in a subgroup of patients aged 8 to <17 years in clinical trials, and the results were consistent with overall study results.

4. Is HAEGARDA suitable for use in geriatric patients?

Clinical studies of HAEGARDA did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects. However, reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for elderly patients should be cautious and typically start at the lower end of the dosing range, considering factors like decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.

Cinryze® Alternatives